Boosting cancer immunosurveillance with vaccines

This Research Topic is intended to build on the first volume of Cancer Immunosurveillance (see here) by focusing specifically on the role of vaccines in strengthening the immune system’s capacity to detect, prevent, and treat cancer. Contributions to this Research Topic are expected to address how vaccination can induce or amplify humoral and cellular anti-tumor responses at various stages of tumor development, from premalignant lesions and hereditary cancer syndromes through to established and recurrent disease, and how these approaches intersect with the broader goal of restoring effective immunosurveillance.The problem to be addressed is how vaccination strategies can be designed and optimized to prevent, intercept, or treat cancer by harnessing the immune system’s natural surveillance mechanisms. This Research Topic covers preventive, interceptive, and therapeutic cancer vaccines, along with the antigen discovery, delivery technologies, and combination strategies that support them. Advances to be covered include tumor-associated antigen and neoantigen identification and selection, novel vaccine platforms and delivery technologies, adjuvant and combination approaches to enhance immunogenicity, and the immunological correlates that indicate a vaccine is successfully engaging humoral and cellular anti-tumor immunity. We welcome manuscripts focusing on, but not limited to, the following themes:• Preventive cancer vaccines, including approaches for hereditary cancer syndromes and premalignant or high-risk conditions• Therapeutic cancer vaccines for the treatment of established or recurrent malignancy• Tumor antigen selection for vaccine design (shared tumor-associated antigens versus individual mutated neoantigens)• Novel vaccine platforms, delivery technologies, and adjuvant strategies to enhance humoral and cellular immunogenicity• Combination approaches pairing cancer vaccines with checkpoint inhibitors, cytokine-based therapies, or other immunomodulators• Biomarkers and immunological correlates of vaccine-induced protection or response• Clinical and translational studies evaluating cancer vaccine safety, immunogenicity, and efficacyDr. Olivera J. Finn is a member of the external advisory boards of Brenus Pharma and PDS Biotech. All other Topic Editors declare no competing interests with regard to the Research Topic subject. Topic editors: Sam Hanash, Luigi Buonaguro, Olivera J. Finn Source: https://www.frontiersin.org/research-topics/86292/boosting-cancer-immunosurveillance-with-vaccines